From cutting edge science to the impact of Obamacare, from clinical trial results to FDA decisions, and from Bieber fever to hay fever, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments across the health-care industry and their implications for long-term investors. In this week's edition, the team talks about an exciting drug approval, how computers can help scientists develop new drugs, and stocks that have both soared and crashed. The analysts close with a discussion of companies that they'll be closely following in the coming weeks.

In the segment below, health-care analyst Max Macaluso discusses the upcoming FDA decision regarding Johnson & Johnson's (NYSE:JNJ) type 2 diabetes drug Invokana, and how the regulatory agency's opinion could be shaped by a previous rejection of a similar drug developed by Bristol-Myers Squibb (NYSE:BMY) and AstraZeneca (NYSE:AZN).

The relevant video segment can be found between 2:39 and 4:15.

Brenton Flynn has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.